Company
TScan Therapeutics, Inc
Engineering Immunity
Also known as TScan Therapeutics
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Waltham, MA, United States
- Founded
- 2018
- Legal name
- TScan Therapeutics, Inc.
- tscan.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
TScan is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer.
Funding snapshot
- Total raised
- $123MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $100M2021-01-15
Funding rounds
- Round, 2021
- $100M2021-01-15, SEC form D sold, 16 investors
- Round, 2019
- $23.3M2019-07-11, SEC form D sold, 9 investors
Loading relationship preview